Abstract In 2018, studies of radiotherapy for breast cancer mainly focus on three aspects:shorten course of radiotherapy:efficacy and safety of weekly hypofractionated whole breast irradiation (FAST and FAST FORWARD) and dose escalated intensity-modulated radiotherapy to whole breast (IMPORT HIGH);reduction in treatment volume:safety and efficacy of APBI (NSABP/RTOG 0413 and RAPID), and individualize radiotherapy decision:optimization of definition of low-risk breast cancer using clinicopathologic parameters, genomic assays and molecule subtypes. The individualized radiotherapy will be the mainstream orietation of development.
[1] EBCTCG. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials[J]. Lancet, 2005, 366(9503):2087-2106. DOI:10.1016/S0140-6736(05)67887-7. [2] EBCTCG. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death:meta-analysis of individual patient data for10 801women in 17 randomised trials[J]. Lancet, 2011, 378(9804):1707-1716. DOI:10.1016/s0140-6736(11)61629-2. [3] Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer:results of a randomized clinical trial in Lyon, France[J]. J Clin Oncol, 1997, 15(3):963-968. DOI:10.1200/JCO.1997.15.3.963. [4] Haviland JS, Owen JR, Dewar JA, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer:10-year follow-up results of two randomised controlled trials[J]. Lancet Oncol, 2013, 14(11):1086-1094. DOI:10.1016/S1470-2045(13)70386-3. [5] Group TFT. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer:a randomised trial[J]. Lancet, 2008, 371(9618):1098-1107. DOI:10.1016/s0140-6736(08)60348-7. [6] Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer[J]. N Engl J Med, 2010, 362(6):513-520. DOI:10.1056/NEJMoa0906260. [7] Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation:an American society for radiation oncology (ASTRO) evidence-based guideline[J]. Int J Radiat Oncol Biol Phys, 2011, 81(1):59-68. DOI:10.1016/j.ijrobp.2010.04.042. [8] Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast:Executive summary of an American society for radiation oncology (ASTRO) evidence-based guideline[J]. Practical Radiat Oncol, 2018, 8(3):145-152. DOI:10.1016/j.prro.2018.01.012. [9] Group TFT. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)[J]. Radiother Oncol, 2011, 100(1):93-100. DOI:10.1016/j.radonc.2011.06.026. [10] Brunt AM, Haviland J, Sydenham M, et al. FAST phase Ⅲ RCT of radiotherapy hypofractionation for treatment of early breast cancer:10-year results[J]. Int J Radiat Oncol Biol Phys, 2018, 102(5):1603-1604. DOI:10.1016/j.ijrobp.2018.08.049. [11] Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma:long-term results of a randomized trial[J]. Ann Oncol, 2001, 12(7):997-1003. DOI:10.1023/a:1011136326943. [12] Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial):5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial[J]. Lancet, 2017, 390(10099):1048-1060. DOI:10.1016/s0140-6736(17)31145-5. [13] Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision:long-term results of a randomised trial[J]. Lancet Oncol, 2006, 7(6):467-471. DOI:10.1016/s1470-2045(06)70699-4. [14] Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer:long-term results of a randomised trial[J]. Radiother Oncol, 2005, 75(1):9-17. DOI:10.1016/j.radonc.2005.01.005. [15] Whelan T, Mackenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer[J]. J Natl Cancer Inst, 2002, 94(15):1143-1150. DOI:10.1093/jnci/94.15.1143. [16] Group TFT. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer:a randomised trial[J]. Lancet Oncol, 2008, 9(4):331-341. DOI:10.1016/s1470-2045(08)70077-9. [17] Coles C, Yarnold J. The IMPORT trials are launched (September 2006)[J]. Clin Oncol (R Coll Radiol), 2006, 18(8):587-590. DOI:10.1016/j.clon.2006.07.010. [18] Brunt AM, Wheatley D, Yarnold J, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial[J]. Radiother oncol, 2016, 120(1):114-118. DOI:10.1016/j.radonc.2016.02.027. [19] Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer[J]. NEJM, 2015, 373(4):317-327. DOI:10.1056/NEJMoa1415369. [20] Ebctcg, Mcgale P, Taylor C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality:meta-analysis of individual patient data for 8135 women in 22 randomised trials[J]. Lancet, 2014, 383(9935):2127-2135. DOI:10.1016/S0140-6736(14)60488-8. [21] Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer[J]. NEJM, 2015, 373(4):307-316. DOI:10.1056/NEJMoa1415340. [22] Donker M, Van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS):a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014, 15(12):1303-1310. DOI:10.1016/s1470-2045(14)70460-7. [23] Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients withhigh-risk breast cancer:a randomised, non-inferiority, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(3):352-360. DOI:10.1016/s1470-2045(18)30813-1. [24] Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation:Executive summary for the update of an ASTRO evidence-based consensus statement[J]. Pract Radiat Oncol, 2017, 7(2):73-79. DOI:10.1016/j.prro.2016.09.007. [25] Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast:a randomised, phase 3, non-inferiority trial[J]. Lancet, 2016, 387(10015):229-238. DOI:10.1016/s0140-6736(15)00471-7. [26] Polgár C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast:5-year results of a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(2):259-268. DOI:10.1016/s1470-2045(17)30011-6. [27] Olivotto IA, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from RAPID:a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy[J]. J Clin Oncol, 2013, 31(32):4038-4045. DOI:10.1200/jco.2013.50.5511.
2020, Vol. 29 
